-
EP3808762
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3808762
| EP3808762 - FUSION PROTEIN BOUND TO CELL-PERMEABLE PEPTIDE, AND COMPOSITION COMPRISING FUSION PROTEIN OR CELL-PERMEABLE PEPTIDE AND EPITHELIAL CELL GROWTH FACTOR AS ACTIVE INGREDIENTS [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 19.03.2021 Database last updated on 19.10.2024 | |
| Former | The international publication has been made Status updated on 21.12.2019 | Most recent event Tooltip | 29.06.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states Avixgen Inc. 222, Banpo-daero Seocho-gu Seoul 06591 / KR | [2021/16] | Inventor(s) | 01 /
BAEK, Yi Yong 901-601, 10, Hugok-ro, Ilsanseo-Gu Goyang-Si Gyeonggi-do 10375 / KR | 02 /
SHIN, Woo Ri 2-303, 58, Gyeongwon-daero 897beon-gil Michuhol- Gu Incheon 22134 / KR | 03 /
PARK, Si Eun 202ho, 81-5, Heukseok-ro Dongjak-Gu Seoul 06910 / KR | 04 /
CHOI, Jun Sub 108-401, 15, Dunjeon-ro, Pogok-eup, Cheoin-gu Yongin-Si Gyeonggi-do 17027 / KR | 05 /
KOO, Hye Cheong 201-107, 154, Haan-ro Gwangmyeong-Si Gyeonggi-do 14314 / KR | [2021/16] | Representative(s) | Cabinet Nony 11 rue Saint-Georges 75009 Paris / FR | [N/P] |
| Former [2021/16] | Nony 11 rue Saint-Georges 75009 Paris / FR | Application number, filing date | 19819517.4 | 07.06.2019 | [2021/16] | WO2019KR06848 | Priority number, date | KR20180068378 | 14.06.2018 Original published format: KR 20180068378 | [2021/16] | Filing language | KO | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2019240430 | Date: | 19.12.2019 | Language: | KO | [2019/51] | Type: | A1 Application with search report | No.: | EP3808762 | Date: | 21.04.2021 | Language: | EN | [2021/16] | Search report(s) | International search report - published on: | KR | 19.12.2019 | (Supplementary) European search report - dispatched on: | EP | 02.03.2022 | Classification | IPC: | C07K14/33, A61K8/64, A61Q19/00 | [2021/16] | CPC: |
C07K14/485 (EP,US);
C07K14/33 (EP,KR);
A61K8/64 (EP,KR,US);
A61Q19/00 (KR);
A61Q19/08 (EP,US);
C07K1/14 (US);
C07K7/06 (US);
C12N9/52 (US);
A61K38/00 (US);
C07K2319/01 (EP);
C07K2319/10 (EP,KR,US);
C12Y304/24069 (US);
Y02A50/30 (EP)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/16] | Title | German: | FUSIONSPROTEIN, DAS AN ZELLDURCHLÄSSIGES PEPTID GEBUNDEN IST, UND ZUSAMMENSETZUNG ENTHALTEND FUSIONSPROTEIN ODER ZELLDURCHLÄSSIGES PEPTID UND EPITHELZELLWACHSTUMSFAKTOR ALS WIRKSTOFFE | [2021/16] | English: | FUSION PROTEIN BOUND TO CELL-PERMEABLE PEPTIDE, AND COMPOSITION COMPRISING FUSION PROTEIN OR CELL-PERMEABLE PEPTIDE AND EPITHELIAL CELL GROWTH FACTOR AS ACTIVE INGREDIENTS | [2021/16] | French: | PROTÉINE DE FUSION LIÉE À UN PEPTIDE PERMÉABLE AUX CELLULES, ET COMPOSITION COMPRENANT UNE PROTÉINE DE FUSION OU UN PEPTIDE PERMÉABLE AUX CELLULES ET UN FACTEUR DE CROISSANCE DE CELLULES ÉPITHÉLIALES COMME PRINCIPES ACTIFS | [2021/16] | Entry into regional phase | 13.01.2021 | Translation filed | 14.01.2021 | National basic fee paid | 14.01.2021 | Search fee paid | 14.01.2021 | Designation fee(s) paid | 14.01.2021 | Examination fee paid | Examination procedure | 14.01.2021 | Examination requested [2021/16] | 22.09.2022 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 30.06.2021 | Renewal fee patent year 03 | 30.06.2022 | Renewal fee patent year 04 | 30.06.2023 | Renewal fee patent year 05 | 28.06.2024 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [Y]EP3156412 (PROCELL THERAPEUTICS INC [KR], et al) [Y] 1-12 * paragraphs [0012] , [ 0083]; example 13 *; | [Y] - SAMAN A. NASROLLAHI ET AL, "Cell-penetrating Peptides as a Novel Transdermal Drug Delivery System", CHEMICAL BIOLOGY & DRUG DESIGN, (20121101), vol. 80, no. 5, doi:10.1111/cbdd.12008, ISSN 1747-0277, pages 639 - 646, XP055083780 [Y] 1-12 * page 641, column 1, paragraph l - page 643, column 2, paragraph 2; figure 2; table 1 * DOI: http://dx.doi.org/10.1111/cbdd.12008 | [Y] - GIULIA GUIDOTTI ET AL, "Cell-Penetrating Peptides: From Basic Research to Clinics", TRENDS IN PHARMACOLOGICAL SCIENCES., GB, (20170401), vol. 38, no. 4, doi:10.1016/j.tips.2017.01.003, ISSN 0165-6147, pages 406 - 424, XP055440339 [Y] 1-12 * page 419, paragraph l * DOI: http://dx.doi.org/10.1016/j.tips.2017.01.003 | International search | [Y]CN1765929 (POISON MED INST PLA MED ACAD [CN]) [Y] 1-8, 10; | [Y]KR20150056022 (LG HOUSEHOLD & HEALTH CARE LTD [KR]) [Y] 1-8, 10; | [Y]US2015266939 (VOGAN ERIK M [US], et al) [Y] 1-8, 10; | [A]KR101636846B (NEXGEN BIOTECHNOLOGIES INC [KR])[A] 1-8, 10; | [Y]KR20170002475 (PROCELL THERAPEUTICS INC [KR], et al) [Y] 1-8, 10; | [Y] - "Gag [Human immunodeficiency virus 1", GenBank, (20160721), Database accession no. BAA12996.1, XP055669142 [Y] 1-8, 10 |